lifestyle.pluralist.com

Author: Zymeworks Inc.

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

April 9, 2026
Zymeworks Appoints Kristin Stafford as Chief Financial Officer

April 1, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

March 30, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

March 30, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences

March 24, 2026
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

March 18, 2026
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

March 18, 2026
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

March 2, 2026
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

March 2, 2026
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

February 17, 2026